Clinical Trials Logo

Positron-Emission Tomography clinical trials

View clinical trials related to Positron-Emission Tomography.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04982458 Active, not recruiting - Heart Failure Clinical Trials

Visualized Monitoring of Fibrosis Formation in Heart Failure With 68GA-FAPI PET

Start date: August 1, 2021
Phase:
Study type: Observational

This is a diagnostic study. Patients were included from patients with clinically suspected or confirmed heart failure, and 68Ga-FAPI and 13N-NH3 gated myocardial imaging were performed to evaluate the effectiveness of 68Ga-FAPI PET imaging in visualizing the degree of myocardial fibrosis in patients with heart failure. The subjects completed 68Ga-FAPI and 13N-NH3 gated myocardial imaging in a one-stop process, and collected general information, clinical data, echocardiography, blood routine, liver and kidney function indicators, 68Ga-FAPI and 13N-NH3 PET imaging results and other imaging data of the patients and volunteers.

NCT ID: NCT01956409 Active, not recruiting - Clinical trials for Magnetic Resonance Imaging

Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis

Start date: September 2012
Phase: Phase 4
Study type: Interventional

The application of FCH PET in breast cancer diagnosis has not been reported. We hypothesize that FCH reveals choline metabolic profiles of breast cancers, and shows the similar pathophysiological mechanism to choline on proton MRS, and our study goals are: 1. To investigate and compare the diagnostic performance of proton MRS and FCH PET for localized findings on mammography and breast ultrasound. 2. To investigate whether FCH PET findings are correlated with choline signals on proton MRS. 3. To evaluate if choline, water and lipid signals on proton MRS, FCH PET are associated with factors related to clinical outcome and prognosis- that is, molecular markers, tumor staging, histologic grade of breast cancers. 4. For localized advanced breast cancer, to investigate the treatment response to NAC using proton MRS and FCH PET, and to evaluate which modality is more sensitive. 5. To investigate the usefulness of FCH PET for whole body staging for breast cancer patients.